BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9308251)

  • 1. Investigation of aberrant translational control of c-myc in cell lines derived from patients with multiple myeloma.
    Willis AE; Paulin FE; West MJ; Whitney RL
    Curr Top Microbiol Immunol; 1997; 224():269-76. PubMed ID: 9308251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant translational control of the c-myc gene in multiple myeloma.
    Paulin FE; West MJ; Sullivan NF; Whitney RL; Lyne L; Willis AE
    Oncogene; 1996 Aug; 13(3):505-13. PubMed ID: 8760292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of myc-family genes in established human multiple myeloma cell lines: L-myc but not c-myc gene expression in the U-266 myeloma cell line.
    Jernberg-Wiklund H; Pettersson M; Larsson LG; Anton R; Nilsson K
    Int J Cancer; 1992 Apr; 51(1):116-23. PubMed ID: 1563831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated c-myc messenger RNA in multiple myeloma cell lines.
    Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L
    Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered myc gene transcription and intron-induced stabilization of myc RNAs in two mouse plasmacytomas.
    Bauer SR; Piechaczyk M; Nordan RP; Owens JD; Nepveu A; Marcu KB; Mushinski JF
    Oncogene; 1989 May; 4(5):615-23. PubMed ID: 2657576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective expression of one c-myc allele in two human myeloma cell lines.
    Kuehl WM; Brents LA; Chesi M; Bergsagel PL
    Cancer Res; 1996 Oct; 56(19):4370-3. PubMed ID: 8813127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single nucleotide change in the c-myc internal ribosome entry segment leads to enhanced binding of a group of protein factors.
    Paulin FE; Chappell SA; Willis AE
    Nucleic Acids Res; 1998 Jul; 26(13):3097-103. PubMed ID: 9628905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of c-myc-mRNA and c-MYC-protein during terminal neoplastic B-cell differentiation.
    Greil R; Loidl P; Fasching B; Huber H
    Curr Top Microbiol Immunol; 1992; 182():215-21. PubMed ID: 1490357
    [No Abstract]   [Full Text] [Related]  

  • 9. Amplification of the c-myc and the pvt-like region in human multiple myeloma.
    Bakkus MH; Brakel-van Peer KM; Michiels JJ; van 't Veer MB; Benner R
    Oncogene; 1990 Sep; 5(9):1359-64. PubMed ID: 2216459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
    Wen XY; Stewart AK; Sooknanan RR; Henderson G; Hawley TS; Reimold AM; Glimcher LH; Baumann H; Malek LT; Hawley RG
    Int J Oncol; 1999 Jul; 15(1):173-8. PubMed ID: 10375612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells.
    Nobuyoshi M; Kawano M; Tanaka H; Ishikawa H; Tanabe O; Iwato K; Asaoku H; Sakai A; Kuramoto A
    Br J Haematol; 1991 Apr; 77(4):523-8. PubMed ID: 2025578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation.
    Chappell SA; LeQuesne JP; Paulin FE; deSchoolmeester ML; Stoneley M; Soutar RL; Ralston SH; Helfrich MH; Willis AE
    Oncogene; 2000 Sep; 19(38):4437-40. PubMed ID: 10980620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.
    Greil R; Fasching B; Loidl P; Huber H
    Blood; 1991 Jul; 78(1):180-91. PubMed ID: 2070052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
    Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
    Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
    Selvanayagam P; Blick M; Narni F; van Tuinen P; Ledbetter DH; Alexanian R; Saunders GF; Barlogie B
    Blood; 1988 Jan; 71(1):30-5. PubMed ID: 3275475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of c-myc in multiple myeloma.
    Kuehl WM; Brents LA; Chesi M; Huppi K; Bergsagel PL
    Curr Top Microbiol Immunol; 1997; 224():277-82. PubMed ID: 9308252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma.
    Shi Y; Sun F; Cheng Y; Holmes B; Dhakal B; Gera JF; Janz S; Lichtenstein A
    Mol Cancer Ther; 2022 Apr; 21(4):502-510. PubMed ID: 35086951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma.
    Hollis GF; Gazdar AF; Bertness V; Kirsch IR
    Mol Cell Biol; 1988 Jan; 8(1):124-9. PubMed ID: 3275865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation.
    Mezquita P; Parghi SS; Brandvold KA; Ruddell A
    Oncogene; 2005 Jan; 24(5):889-901. PubMed ID: 15580293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interferon alpha on myeloma cells: mechanisms of differential responsiveness.
    Jelinek DF; Arora T
    Curr Top Microbiol Immunol; 1997; 224():261-8. PubMed ID: 9308250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.